

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Evening Phone: \_\_\_\_\_ Daytime Phone: \_\_\_\_\_

Email: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Gender: \_\_\_\_\_

ICD10 Diagnosis Code: \_\_\_\_\_ Primary Diagnosis: \_\_\_\_\_

Chest Circumference: \_\_\_\_\_

(Measure fullest part of chest)

Primary Insurance Provider: \_\_\_\_\_ Secondary Insurance Provider: \_\_\_\_\_

## BELOW THIS LINE TO BE COMPLETED BY A HEALTHCARE PROVIDER ONLY

**Airway Clearance Therapy Tried and Failed. This must be documented in the patient's progress notes.**1. Have alternative airway clearance techniques been **tried and failed**? ☐ YES ☐ NO

Please indicate methods of airway clearance patient has tried and failed (check all that apply):

☐ CPT (manual or percussor)☐ Oscillating PEP (Flutter, Acapella, Aerobika, Pep Valve, Pep Mask)☐ Huff coughing☐ Breathing techniques☐ Mucomyst\*☐ Hypertonic saline☐ Suctioning

(\*Notes must document it is prescribed for secretion mobilization)

2. Check all reasons why the above therapy failed, is contraindicated or inappropriate for this patient:

☐ Cannot tolerate positioning/hand CPT☐ Too fragile for hand CPT☐ Did not mobilize secretions☐ Other☐ Physical limitations of caregiver☐ Caregiver unable to perform adequate CPT☐ Insufficient expiratory force☐ Gastroesophageal reflux (GERD)☐ Severe arthritis, osteoporosis☐ Resistance to therapy☐ Cognitive level☐ Unable to form mouth seal☐ Artificial airway

3. For Cystic Fibrosis or Neuromuscular patients, the following must be documented in the patient's progress notes. Please attach records with Rx.

☐ Documentation supporting diagnosis☐ Tried and failed a lesser airway clearance technique indicated above

4. For Bronchiectasis patients, please check Yes or No to the following question:

Has there been a CT scan confirming Bronchiectasis diagnosis? ☐ YES ☐ NO If "Yes" please include copy of CT scan interpretation.

In addition, the following medical history in the past year must be documented in the patient's progress notes. Please attach records with Rx.

☐ More than two exacerbations, i.e., lung infections, requiring antibiotics in the last 12 months, documented at least two separate times**OR**☐ Daily productive cough for more than six continuous months**Rx: High Frequency Chest Wall Oscillation (HFCWO HCPCS E0483)**Start Date: \_\_\_\_\_ Check need of Length: ☐ Lifetime (99) ☐ Other \_\_\_\_\_☐ Dispense one AffloVest by Tactile Medical/High Frequency Chest Wall Oscillation System/E0483☐ Frequency of use (standard): Use the AffloVest at low, medium or high for 30 minute treatments twice per day☐ Frequency of use (custom): Use the AffloVest at (**select a box**) ☐ low, ☐ medium or ☐ high for \_\_\_\_\_ minutes \_\_\_\_\_ times per day☐ Please check box if nebulizer therapy to be used in conjunction with HFCWO

Physician Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Physician Printed Name: \_\_\_\_\_ NPI Number: \_\_\_\_\_

Physician Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Physician Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Alternate Contact: \_\_\_\_\_ Phone: \_\_\_\_\_ Email: \_\_\_\_\_

Designated DME: \_\_\_\_\_

I certify the accuracy of this Rx for the AffloVest Airway Clearance System and that I am the physician identified in this form. I certify that the medical information provided above and in the supplementary documentation is true, accurate, and completed to the best of my knowledge. The patient record contains the supplementary documentation to substantiate the medical necessity of the AffloVest and physician notes will be provided to the authorized AffloVest distributor by request. By providing this form to an authorized AffloVest distributor, I acknowledge that the patient is aware that he or she may be contacted by said distributor for any additional information to process this order.

\*AffloVest requires a doctor's prescription for treatment by High Frequency Chest Wall Oscillation (HFCWO). The AffloVest has received the FDA's 510k clearance for U.S. market availability, and is approved for Medicare, Medicaid and private health insurance reimbursement under the Healthcare Common Procedure Coding System (HCPCS) code E0483 – High Frequency Chest Wall Oscillation. The AffloVest is also available through the U.S. Department of Veterans Affairs/Tricare. Patients must qualify to meet insurance eligibility requirements.

Durable Medical Equipment companies are ultimately responsible for ensuring that the reimbursement criteria for a specific insurance plan and patient situation are satisfied.

# Medicare Approved ICD-10 Codes for AffloVest HFCWO Therapy (HPCS E0483)

## Medicare Requirements for Bronchiectasis:

1. Required: CT scan confirming diagnosis of bronchiectasis.

**AND**

2. Required: Daily productive cough for more than six continuous months.

**OR**

Frequent (i.e., more than two/year) exacerbations requiring antibiotic therapy in the last 12 months.

**AND**

3. Required: Documentation (chart notes) of another treatment tried to mobilize secretions and clearly indicating the other technique or device has failed.

### ICD-10 CODE DESCRIPTION

|       |                                                       |
|-------|-------------------------------------------------------|
| J47.0 | Bronchiectasis with acute lower respiratory infection |
| J47.1 | Bronchiectasis with (acute) exacerbation              |
| J47.9 | Bronchiectasis, uncomplicated                         |
| Q33.4 | Congenital bronchiectasis                             |

## Medicare Requirements for Other Respiratory, Cystic Fibrosis and Neuromuscular Conditions\*:

Physician's order that includes: AffloVest prescription, qualifying Dx, chart notes to support the Dx and well-documented failure of standard treatments to adequately mobilize retained secretions.

### ICD-10 CODE/DESCRIPTION

#### Bronchiectasis

|       |                                                       |
|-------|-------------------------------------------------------|
| J47.0 | Bronchiectasis with acute lower respiratory infection |
| J47.1 | Bronchiectasis with (acute) exacerbation              |
| J47.9 | Bronchiectasis, uncomplicated                         |
| Q33.4 | Congenital bronchiectasis                             |

#### Cystic Fibrosis

|       |                                               |
|-------|-----------------------------------------------|
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| E84.9 | Cystic fibrosis, unspecified                  |

#### Infectious/Immune

|       |                      |
|-------|----------------------|
| A15.0 | Tuberculosis of lung |
|-------|----------------------|

#### Poliomyelitis

|     |                           |
|-----|---------------------------|
| B91 | Sequelae of poliomyelitis |
| G14 | Postpolio syndrome        |

#### Myotonic/Metabolic Disorders

|        |                                                           |
|--------|-----------------------------------------------------------|
| E74.02 | Pompe disease                                             |
| E74.05 | Lysosome-associated membrane protein 2 [LAMP2] deficiency |
| G71.11 | Myotonic muscular dystrophy                               |
| G71.12 | Myotonia congenita                                        |
| G71.13 | Myotonic chondrodystrophy                                 |
| G71.14 | Drug induced myotonia                                     |
| G71.19 | Other specified myotonic disorders                        |

#### Motor Neuron/Neuromuscular/Anterior Horn Cell Disease

|        |                                                             |
|--------|-------------------------------------------------------------|
| G12.0  | Infantile spinal muscular atrophy, type I [Werdnig-Hoffman] |
| G12.1  | Other inherited spinal muscular atrophy                     |
| G12.20 | Motor neuron disease, unspecified                           |
| G12.21 | Amyotrophic lateral sclerosis                               |
| G12.22 | Progressive bulbar palsy                                    |
| G12.23 | Primary lateral sclerosis                                   |
| G12.24 | Familial motor neuron disease                               |
| G12.25 | Progressive spinal muscle atrophy                           |
| G12.29 | Other motor neuron disease                                  |
| G12.8  | Other spinal muscular atrophies and related syndromes       |
| G12.9  | Spinal muscular atrophy, unspecified                        |

#### Multiple Sclerosis

|        |                                     |
|--------|-------------------------------------|
| G35.A  | Relapsing remitting MS              |
| G35.B0 | Primary progressive MS              |
| G35.B1 | Active primary progressive MS       |
| G35.B2 | Non-active primary progressive MS   |
| G35.C0 | Secondary progressive MS            |
| G35.C1 | Active secondary progressive MS     |
| G35.C2 | Non-active secondary progressive MS |
| G35.D  | Multiple sclerosis, unspecified     |

#### Muscular Dystrophy

|        |                                         |
|--------|-----------------------------------------|
| G71.00 | Muscular dystrophy, unspecified         |
| G71.01 | Duchenne or Becker muscular dystrophy   |
| G71.02 | Fascioscapulohumeral muscular dystrophy |

|          |                                                                                 |
|----------|---------------------------------------------------------------------------------|
| G71.031  | Autosomal dominant limb girdle muscular dystrophy                               |
| G71.032  | Autosomal recessive limb girdle muscular dystrophy due to calpain-3 dysfunction |
| G71.033  | Limb girdle muscular dystrophy due to dysferlin dysfunction                     |
| G71.0340 | Limb girdle muscular dystrophy due to sarcoglycan dysfunction, unspecified      |
| G71.0341 | Limb girdle muscular dystrophy due to alpha sarcoglycan dysfunction             |
| G71.0342 | Limb girdle muscular dystrophy due to beta sarcoglycan dysfunction              |
| G71.0349 | Limb girdle muscular dystrophy due to other sarcoglycan dysfunction             |
| G71.035  | Limb girdle muscular dystrophy due to anoctamin-5 dysfunction                   |
| G71.036  | Limb girdle muscular dystrophy due to fukutin related protein dysfunction       |
| G71.038  | Other limb girdle muscular dystrophy                                            |
| G71.039  | Limb girdle muscular dystrophy, unspecified                                     |
| G71.09   | Other specified muscular dystrophies                                            |

#### Disorders of the Diaphragm

|       |                        |
|-------|------------------------|
| J98.6 | Disorders of diaphragm |
|-------|------------------------|

#### Myopathies

|         |                                                                    |
|---------|--------------------------------------------------------------------|
| G71.20  | Congenital myopathy, unspecified                                   |
| G71.21  | Nemaline myopathy                                                  |
| G71.220 | X-linked myotubular myopathy                                       |
| G71.228 | Other centronuclear myopathy                                       |
| G71.29  | Other congenital myopathy                                          |
| G71.3   | Mitochondrial myopathy, not elsewhere classified                   |
| G71.8   | Other primary disorders of muscles                                 |
| G72.0   | Drug-induced myopathy                                              |
| G72.1   | Alcoholic myopathy                                                 |
| G72.2   | Myopathy due to other toxic agents                                 |
| G72.41  | Inclusion body myositis [IBM]                                      |
| G72.49  | Other inflammatory and immune myopathies, not elsewhere classified |
| G72.89  | Other specified myopathies                                         |
| G72.9   | Myopathy, unspecified                                              |
| G73.7   | Myopathy in diseases classified elsewhere                          |
| M33.02  | Juvenile dermatomyositis with myopathy                             |
| M33.12  | Other dermatomyositis with myopathy                                |
| M33.22  | Polymyositis with myopathy                                         |
| M33.92  | Dermatopolymyositis, unspecified with myopathy                     |
| M34.82  | Systemic sclerosis with myopathy                                   |
| M35.03  | Sicca syndrome with myopathy                                       |

#### Quadriplegia

|        |                                     |
|--------|-------------------------------------|
| G80.0  | Spastic quadriplegic cerebral palsy |
| G82.50 | Quadriplegia, unspecified           |
| G82.51 | Quadriplegia, C1-C4 complete        |
| G82.52 | Quadriplegia, C1-C4 incomplete      |
| G82.53 | Quadriplegia, C5-C7 complete        |
| G82.54 | Quadriplegia, C5-C7 incomplete      |

#### Myasthenia Gravis

|        |                                              |
|--------|----------------------------------------------|
| G70.00 | Myasthenia gravis without acute exacerbation |
| G70.01 | Myasthenia gravis with acute exacerbation    |

\*cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33785&ContrlD=140

#### Tactile Medical

3701 Wayzata Blvd, Suite 300    Toll Free Tel: 800.575.1900  
Minneapolis, MN 55416 USA    Toll Free Fax: 866.569.1912    afflovest.com

©2026 Tactile Medical. All rights reserved. AffloVest and Tactile Medical are registered trademarks of Tactile Medical. 702025-001 Rev K 5/2026

**Tactile**  
MEDICAL®